Alliance-A151216: Adjuvant Lung Cancer enrichment marker identification and sequencing trial (Alchemist)

The purpose of the study is to examine lung cancer patients’ surgically removed tumors for certain genetic changes and to possibly refer these patients to a treatment study with the drugs that may specifically target tumors that have the genetic changes.

Learn more about Alliance-A151216 trial or contact the Protocol Office at 484-628-8193.

NON-SMALL CELL

NRG-LU002: Maintenance systemic therapy versus consolidative stereotactic body radiation therapy (SBRT) plus maintenance systemic therapy for limited metastatic non- small cell lung cancer (NSCLC); A Randomized Phase II/III Trial.

The purpose of this study is to compare any good and bad effects of using the usual drug therapy plus radiation to treat the lung cancer and the areas of metastasis (where the cancer has spread) compared with the usual drug therapy alone.

Learn more about the NRG-LU002 trial or contact the Protocol Office at 484-628-8193.

Alliance-A081105: Erlotinib hydrochloride in treating patients with stage IB- IIIA non-small cell lung cancer that has been completely removed by surgery (an Alchemist Treatment Trial)

The purpose of this study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).

Learn more about Alliance-A081105 trial or contact the Protocol Office at 484-628-8193.

ECOG/ACRIN E4512: Crizotinib in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and ALK fusion mutations (an Alchemist Treatment Trial)

The purpose of this study is to compare any good and bad effects of using the study drug, crizotinib (also known as Xalkori), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer.

Learn more about ECOG/ACRIN E4512 trial or contact the Protocol Office at 484-628-8193

Alliance-A081801: Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO.

The purpose of this study is to compare the usual treatment alone to using pembrolizumab plus the usual treatment.

Learn more about the Alliance-A081801 trial or call the Protocol Office at 484-628-8193.

NCMGA0012-304/Incyte: A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304).

The purpose of this study is to compare the effects and safety of INCMGA00012 in combination with chemotherapy (“investigational combination”) compared to placebo in combination with chemotherapy in participants with NSCLC.

Learn more about the INCMGA0012-304/Incyte trial or call the Protocol Office at 484-628-8193.

SMALL CELL

NRG-CC003: A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation to the usual whole-brain radiation.

Learn more about the NRG-CC003 trial or contact the Protocol Office at 484-628-8193.

NRG-LU005: Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer

The purpose of this study is to compare the usual treatment to atezolizumab plus the usual treatment.

Learn more about the NRG-LU005 trial or contact the Protocol Office at 484-628-8193.